|
1H NMR STUDIES OF NON-HODGKINS LYMPHOMA
|
5R01CA101700-07
|
$343,695
|
GLICKSON, JERRY
|
UNIVERSITY OF PENNSYLVANIA
|
|
A bifunctional nanomedicine for both specific imaging and targeting therapy of an
|
5R01CA151955-02
|
$309,964
|
ZU, YOULI
|
METHODIST HOSPITAL RESEARCH INSTITUTE
|
|
A cohort study among workers exposed to benzene in China
|
ZIA CP010120-02060
|
$213,606
|
Rothman, Nat
|
DCEG (NCI)
|
|
A Fourth Outcome: DNA Damage and the Differentiation of B Cells
|
1R01CA156674-01
|
$314,884
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
A High Throughput Protein Complementation Assay for Inhibitors of NEMO-K13 Intera
|
5R01CA139119-02
|
$260,852
|
Chaudhary, Preet
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
A Modifier of Plasmacytoma Susceptibility Maps to Mouse Chr 1
|
ZIA BC 011064
|
$243,917
|
Mock, Beverly
|
CCR (NCI)
|
|
A multi-center international hospital-based case-control study of lymphoma in Asi
|
ZIA CP010136-10512
|
$337,239
|
Lan, Qing
|
DCEG (NCI)
|
|
A MULTILEVEL APPROACH TO ENERGY BALANCE AND CANCER ACROSS THE LIFECOURSE
|
1U54CA155496-01
|
$1,814,496
|
COLDITZ, GRAHAM
|
WASHINGTON UNIVERSITY
|
|
A new small molecule targeting agent and therapeutic for non-Hodgkin's lymphoma
|
1R43CA159843-01
|
$149,959
|
Balhorn, Rodney
|
SHAL TECHNOLOGIES, INC.
|
|
A novel enzymatic activity of WSTF and its role in tumorigenesis
|
5R00CA131560-04
|
$241,530
|
Xiao, zhuo
|
YALE UNIVERSITY
|
|
A Phase I trial combining fenretinide and safingol to target overproduction of di
|
1R21CA161889-01
|
$323,700
|
MAURER, BARRY
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
|
A prospective analysis of peripheral blood cytokines and non-Hodgkin lymphoma
|
1R01CA149445-01A1
|
$617,616
|
BIRMANN, BRENDA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
A Role for KSHV in the Pathogenesis of Malignancies
|
ZIA SC 010356
|
$370,199
|
Tosato, Giovanna
|
CCR (NCI)
|
|
Abramson Cancer Center Support Grant
|
2P30CA016520-35
|
$7,696,742
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-35S1
|
$50,000
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abrogating human CD59 activity for antibody-based cancer therapy
|
5R21CA141324-02
|
$214,562
|
Qin, Xuebin
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
|
Academic Training in Medical Oncology
|
3T32CA009297-28S1
|
$66,919
|
RIBAS, ANTONI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Academic Training in Medical Oncology
|
5T32CA009297-28
|
$316,308
|
RIBAS, ANTONI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Activation of BCL-2 in Hematologic Malignancies
|
5R01CA056764-17
|
$281,785
|
BOXER, LINDA
|
PALO ALTO INSTITUTE FOR RES & EDU, INC.
|
|
Activation of Proto-Oncogenes by Chromosomal Translocation
|
ZIA SC 010378
|
$328,740
|
Aplan, Peter
|
CCR (NCI)
|
|
AIDS and Cancer Specimen Resource Central Office and Data Coordinating Center
|
5U01CA096230-09
|
$731,978
|
MCGRATH, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
AIDS Associated Lymphoproliferative Disorders
|
5R37CA037295-28
|
$390,425
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
3U01CA121947-04S1
|
$200,000
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
3U01CA121947-04S2
|
$450,000
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
3U01CA121947-04S3
|
$150,000
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
5U01CA121947-05
|
$5,189,968
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011415
|
$58,058
|
Kochenderfer, James
|
CCR (NCI)
|
|
Allotransplant for DOCK8 deficiency
|
ZIA BC 011374
|
$157,995
|
Hickstein, Dennis
|
CCR (NCI)
|
|
Altered cellular bioenergetics influences NKT cell mediated responses to Lymphoma
|
1R21CA162277-01
|
$195,750
|
Webb, Tonya
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
An Exercise Intervention to Improve Health in Postmenopausal Cancer Survivors
|
5R01CA122658-05
|
$361,253
|
KNOBF, M. Tish
|
YALE UNIVERSITY
|
|
Analysis of Epstein Barr virus type III latency on cellular miRNA gene expression
|
5R01CA130752-04
|
$299,900
|
FLEMINGTON, ERIK
|
TULANE UNIVERSITY OF LOUISIANA
|
|
Analysis of the p53 in vivo using a unique mouse model
|
5R01CA100193-09
|
$334,263
|
EVAN, GERARD
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,179,485
|
Oberholtzer, J.
|
CCR (NCI)
|
|
Animal Model and Genotyping Core Support Facility
|
ZIC BC 011047
|
$1,220,780
|
DuBois, Wendy
|
CCR (NCI)
|
|
Anti-viral DC/NK interactions
|
5R01CA108609-08
|
$176,961
|
MUNZ, CHRISTIAN
|
UNIVERSITY OF ZURICH
|
|
Antibody Engineering for Therapy and Diagnosis of Hematologic Malignancies
|
ZIA BC 010647
|
$388,021
|
Rader, Christoph
|
CCR (NCI)
|
|
Antibody-based therapeutics and vaccines against AIDS
|
ZIA BC 011155
|
$178,463
|
Dimitrov, Dimiter
|
CCR (NCI)
|
|
Antibody-CpG conjugates for the treatment of B cell lymphoma
|
5R01CA149254-02
|
$309,964
|
Timmerman, John
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Antibody-interferon fusion proteins for treatment of B-cell malignancies
|
1R01CA162964-01
|
$319,550
|
MORRISON, SHERIE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Antibody-mediated Gene Therapy for the Treatment of Cancer
|
5K01CA138559-03
|
$142,677
|
Daniels, Tracy
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Approaches to discover and quantify apoptotic biomarkers for cancer treatment
|
1R01CA154802-01
|
$320,588
|
WELLS, JAMES
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-33S1
|
$139,575
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-33S2
|
$75,000
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
5P30CA023074-33
|
$3,953,813
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
ATBC Study
|
ZIA CP010195-03031
|
$828,679
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011413
|
$116,117
|
Kochenderfer, James
|
CCR (NCI)
|
|
B Cell Lymphoma Therapy
|
5R01CA121039-05
|
$236,918
|
CHOI, YONG
|
OCHSNER CLINIC FOUNDATION
|
|
Basis for Lymphomagenesis in Akt2 Transgenic Mice
|
5R01CA077429-12
|
$419,987
|
TESTA, JOSEPH
|
FOX CHASE CANCER CENTER
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-22
|
$406,165
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-05S1
|
$75,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|